Sutro Biopharma, Inc.: quarterly results

STRONASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$9.82

November 13, 2026Market cap $163M

DCF calculator

What Ploutos Investor adds for Sutro Biopharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from 2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Results, quarter by quarter

When the company put out each quarter's results (its 8-K, item 2.02), what they showed against the same quarter a year before, and how the stock moved on the first session after.

Nov 12, 2026 last results

Next results

in 89 daysAround Feb 12, 2027 · for Q4 2026

last Nov 12, 2026next Feb 12, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

The first session after results

±7.3%average move, either way

3 times upof the last 41 times down

Largest: -14.9% on Aug 12, 2026 (Q2 2026).

How the stock moved after each release

The close of the first session after the results against the close before them.

STRO that sessionS&P 500 the same day

Every release

Revenue and diluted EPS of the quarter reported, with the change against the same quarter a year before.

  • Q3 2026
    Stock, next session+2.4%
  • Q2 2026
    Stock, next session-14.9%
  • Q1 2026
    Stock, next session+1.4%
  • Q4 2025
    Stock, next session+10.5%

Every release

STRO's results days and the share's move after each, from Q3 2018 to Q3 2025, 31 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 8 quarters.

Times are the SEC's acceptance of the 8-K, in New York time: before 16:00 the market traded on it that day, after it the next day. A move on a results day has other causes too, and says nothing about the next one.

The full analysis

What do Sutro Biopharma's filings show?

The results say what Sutro Biopharma reported. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.